Search

everythinglearnresearchcommunity

for

Search:↓

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

Pueraria mirifica extract may help treat benign prostatic hyperplasia.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

The research found that androgens help control blood flow in the rat prostate through a specific binding site.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

No link found between hair loss severity and PSA levels in men.

Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.

Serum triglyceride levels are not linked to prostate cancer risk.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.

Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.

Hair loss is linked to higher prostate-specific antigen levels and urinary symptoms, likely due to age.

Created microspheres show potential for safe and effective use in prostate artery embolization.